Status:
COMPLETED
Genetic Basis for Variation in the Renal Elimination of Metformin
Lead Sponsor:
University of California, San Francisco
Conditions:
Other Conditions That May Be A Focus of Clinical Attention
Eligibility:
All Genders
18-40 years
Phase:
PHASE4
Brief Summary
The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. We will study individuals with particular genotypes of the human org...
Detailed Description
The drug, which is used in the treatment of Type II diabetes, has a narrow therapeutic range. Its net renal clearance by secretion (i.e., renal clearance minus filtration clearance) ranges from approx...
Eligibility Criteria
Inclusion
- Subjects have previously participated in the Study Of Pharmacogenetics In Ethnically Diverse Populations (SOPHIE) study.
- 18-40 years old
- Possess a pre-specified genotype for OCT2
Exclusion
- Taking any regular medications other than vitamins.
- Individuals with anemia (hemoglobin \< 12 g/dL), an elevation in liver enzymes to higher than double the respective normal value, or elevated creatinine concentrations (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL)
- Pregnant or breastfeeding
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00187720
Start Date
May 1 2002
End Date
April 1 2008
Last Update
January 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco General Hospital
San Francisco, California, United States, 94143